The effect of etanercept and infliximab on the production of tumour necrosis factor α, interferon-γ and GM-CSF in in vivo activated intestinal T lymphocyte cultures

This publication has 35 references indexed in Scilit:

• In situ Activated Intestinal T Cells Expanded in vitro – without Addition of Antigen – Produce IFN-γ and IL-10 and Preserve Their Function during Growth
  Experimental and Clinical Immunogenetics, 2001
• CYTOKINE-INDUCED IMPAIRMENT OF SHORT-CHAIN FATTY ACID OXIDATION AND VIABILITY IN HUMAN COLONIC EPITHELIAL CELLS
  Cytokine, 2000
• Immunotherapy of Crohn's Disease
  Scandinavian Journal of Immunology, 2000
• Infliximab for the Treatment of Fistulas in Patients with Crohn's Disease
  New England Journal of Medicine, 1999
• Tumor necrosis factor α antibody (infliximab) therapy profoundly down-regulates the inflammation in Crohn's ileocolitis
  Published by Elsevier ,1999
• Protein transport and processing by human HT29-19A intestinal cells: effect of interferon gamma
  Gut, 1998
• Breakdown of tolerance to the intestinal bacterial flora in inflammatory bowel disease (IBD)
  Clinical and Experimental Immunology, 1995
• Chimeric anti-TNF-α monoclonal antibody cA2 binds recombinant transmembrane TNF-α and activates immune effector functions
  Cytokine, 1995
• The 26-kD transmembrane form of tumor necrosis factor alpha on activated CD4+ T cell clones provides a costimulatory signal for human B cell activation.
  The Journal of Experimental Medicine, 1993
• Triggered human mucosal T cells release tumour necrosis factor-alpha and interferon-gamma which kill human colonic epithelial cells
  Clinical and Experimental Immunology, 1991